The State Administration for Market Regulation convened a press conference to unveil the accomplishments of a dedicated antitrust enforcement initiative within the people's livelihood domain. This three-year drive, primarily targeting the pharmaceutical industry, delivered striking outcomes. A total of 12 significant typical cases were probed, resulting in fines and confiscations amounting to over 2.4 billion yuan. This initiative has catalyzed price reductions exceeding 90% for certain pharmaceuticals, significantly easing the financial strain of medication expenses on patients and curbing national healthcare insurance outlays.
